Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Jul 9, 3:05PM CDT

BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...

OCUL : 10.20 (-3.23%)
TLYS
3 Small-Cap Stocks with Open Questions StockStory - Tue Jul 7, 11:34PM CDT

3 Small-Cap Stocks with Open Questions

BCC : 76.06 (+5.29%)
TLYS : 4.12 (-1.44%)
OCUL : 10.20 (-3.23%)
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences GlobeNewswire - Wed Jul 1, 6:00AM CDT

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 10.20 (-3.23%)
OCUL
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings? StockStory - Tue Jun 23, 11:05PM CDT

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?

OCUL : 10.20 (-3.23%)
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jun 22, 3:05PM CDT

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...

OCUL : 10.20 (-3.23%)
NU
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos StockStory - Thu Jun 18, 8:00AM CDT

Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos

MDLZ : 58.83 (+0.91%)
NU : 13.76 (+0.66%)
RMD : 203.87 (-2.20%)
SONO : 14.50 (+2.98%)
OCUL : 10.20 (-3.23%)
OCUL
Why Ocular Therapeutix (OCUL) Stock Is Up Today StockStory - Wed Jun 17, 11:46AM CDT

Why Ocular Therapeutix (OCUL) Stock Is Up Today

OCUL : 10.20 (-3.23%)
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026 GlobeNewswire - Wed Jun 17, 7:45AM CDT

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach...

OCUL : 10.20 (-3.23%)
LOW
3 of Wall Street’s Favorite Stocks That Concern Us StockStory - Tue Jun 9, 11:37PM CDT

3 of Wall Street’s Favorite Stocks That Concern Us

WH : 78.54 (-1.68%)
LOW : 211.63 (-0.64%)
OCUL : 10.20 (-3.23%)
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jun 5, 6:00AM CDT

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...

OCUL : 10.20 (-3.23%)

Barchart Exclusives

Forget GPUs. Nvidia’s Next AI Gold Mine Could Be Even Bigger. Barchart - 22 minutes ago
Wall Street sees Nvidia's Vera CPU as a major growth catalyst that could expand its AI leadership beyond graphics chips. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.